Abstract
We thank Gonzales et al for their valuable comments on the article on biomarkers from The Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial.1 The RE-LY trial included 18 113 patients with atrial fibrillation, cardiac biomarkers were analyzed from plasma samples obtained at randomization in 6189 of the participants. The results showed that both N-terminal pro-B-type natriuretic peptide (NT-proBNP) and troponin I were strongly and independently related to thromboembolic outcomes regardless of clinical risk factors including heart failure. At randomization, all patients were classified as either having heart failure or not based on New York Heart Association class and on available information regarding previous measurements of left ventricular ejection fraction based on echocardiography, radionuclide, or angiogram assessments.2 NT-proBNP is a sensitive biomarker of left ventricular function, clinical heart failure, and a predictor of …
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
